Austin has concluded work on the site-wide planning and design of a new vaccine manufacturing facility in Korea. The plant will be a dual purpose unit to deal with commercial production and also contract manufacturing. The design will meet the local current regulatory compliance requirements (KGMP), Europe (EU-GMP) and USA (cGMP).

The facility will contain API manufacturing, finished product manufacturing, quality control, quality assurance, automated product cold store, administration areas and support, waste water treatment, warehouse, packaging and shipping areas.